It looks increasingly likely that cancer vaccine Provenge could get EU approval.
Shares of Dendreon popped nearly 10% Friday morning on news coming out of Europe. The CHMP, which is Europe's version of an FDA advisory committee, recommended that the biotech's prostate cancer vaccine, Provenge, be approved.
In this video, health care analyst David Williamson discusses what this recommendation means for Provenge's chances of approval, Dendreon's likely next move, and whether this will serve as a catalyst for shares going forward.
Follow David on Twitter: @MotleyDavid.
David Williamson owns shares of Johnson & Johnson. Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
